# R3HDML

## Overview
The R3HDML gene encodes the R3H domain containing like protein, which is a secretory protein characterized by a signal sequence, a CAP domain, and a furin cleavage sequence. This protein is involved in various cellular processes, particularly in podocyte function and skeletal muscle development. The CAP domain suggests a role in extracellular signaling, as it is associated with cysteine-rich secretory proteins, antigen 5, and pr-1 across different species (Sakamoto2019R3hdml; Ishikawa2021A). R3HDML is implicated in the inhibition of TGF-β-induced p38 MAPK phosphorylation, which is crucial for maintaining the integrity of the glomerular basement membrane and reducing podocyte apoptosis (Ishikawa2021A). In skeletal muscle, it regulates satellite cell proliferation and differentiation, essential for muscle repair and regeneration (Sakamoto2019R3hdml). The gene's expression is modulated by MyoD, highlighting its importance in muscle development (Sakamoto2019R3hdml). R3HDML's potential as a therapeutic target is under investigation, given its involvement in conditions such as diabetic nephropathy and muscle-related diseases (Sakamoto2019R3hdml; Ishikawa2021A).

## Structure
The R3HDML protein consists of 253 amino acids and features a signal sequence at the N-terminal end, a CAP domain in the middle, and a furin cleavage sequence at the C-terminal end (Sakamoto2019R3hdml; Ishikawa2021A). The CAP domain is associated with cysteine-rich secretory proteins in mammals, antigen 5 in insects, and pr-1 in plants, indicating a role in various biological processes (Ishikawa2021A). The presence of a signal sequence suggests that R3HDML is a secretory protein, and the furin cleavage site implies that the protein undergoes cleavage before secretion, resulting in a smaller protein observed in conditioned medium (Sakamoto2019R3hdml).

The protein is predicted to have a molecular weight of approximately 28 kDa, but a cleaved form of around 21 kDa is detected, indicating post-translational modification through proteolytic cleavage (Sakamoto2019R3hdml). The specific details of the secondary, tertiary, and quaternary structures of R3HDML are not provided in the available context. The protein's role in inhibiting TGF-β-induced p38 MAPK phosphorylation and its involvement in podocyte and skeletal muscle functions suggest it may interact with other proteins or receptors, although the exact mechanisms remain unclear (Sakamoto2019R3hdml; Ishikawa2021A).

## Function
The R3HDML gene encodes a protein that plays a significant role in cellular processes related to podocyte function and skeletal muscle development. In podocytes, R3HDML is involved in maintaining the structure and function of the glomerular basement membrane (GBM) by inhibiting the phosphorylation of p38 MAPK, a pathway activated by transforming growth factor-β (TGF-β). This inhibition reduces podocyte apoptosis, which is crucial for preserving glomerular function, particularly under diabetic conditions (Ishikawa2021A). R3HDML is secreted from podocytes and contains a signal sequence, a CAP domain, and a furin cleavage sequence, indicating its role in extracellular signaling (Ishikawa2021A).

In skeletal muscle, R3HDML is expressed in satellite cells and is essential for muscle development and regeneration. It regulates satellite cell proliferation and differentiation, processes critical for muscle repair. The gene's expression is induced during muscle differentiation and is controlled by MyoD, a key regulator of muscle development (Sakamoto2019R3hdml). R3HDML's involvement in these processes suggests its potential as a therapeutic target for conditions like diabetic nephropathy and muscle-related diseases (Sakamoto2019R3hdml; Ishikawa2021A).

## Clinical Significance
The clinical significance of the R3HDML gene is not fully understood, but it has been implicated in several conditions. In oral squamous cell carcinoma (OSCC), R3HDML is associated with a favorable prognosis. Higher expression levels of R3HDML correlate with longer survival rates in OSCC patients, suggesting its potential role as a prognostic marker (Wu2019Screening). However, the molecular mechanisms by which R3HDML influences OSCC remain largely unexplored, and further research is needed to confirm these associations through experimental validation (Wu2019Screening).

In the context of muscular dystrophy, R3HDML has been identified as an inhibitor of peptidase activity in the Dmd mdx /Large myd -/ - model, although its specific functions in this and other diseases are not well-documented (Almeida2016Comparative). Additionally, genome-wide association studies have identified the R3HDML gene in association with type 2 diabetes (T2D) risk alleles in East Asian populations, though the clinical significance of these findings is not detailed (Prasad2015Genetics). Overall, while R3HDML shows potential relevance in various diseases, its precise role and impact require further investigation.


## References


[1. (Sakamoto2019R3hdml) Kenichi Sakamoto, Yasuro Furuichi, Masashi Yamamoto, Megumi Takahashi, Yoshihiro Akimoto, Takahiro Ishikawa, Takahiko Shimizu, Masanori Fujimoto, Aki Takada‐Watanabe, Aiko Hayashi, Yoshitaka Mita, Yasuko Manabe, Nobuharu L Fujii, Ryoichi Ishibashi, Yoshiro Maezawa, Christer Betsholtz, Koutaro Yokote, and Minoru Takemoto. R3hdml regulates satellite cell proliferation and differentiation. EMBO reports, September 2019. URL: http://dx.doi.org/10.15252/embr.201947957, doi:10.15252/embr.201947957. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.15252/embr.201947957)

[2. (Almeida2016Comparative) Camila F Almeida, Poliana CM Martins, and Mariz Vainzof. Comparative transcriptome analysis of muscular dystrophy models largemyd, dmdmdx/largemyd and dmdmdx: what makes them different? European Journal of Human Genetics, 24(9):1301–1309, March 2016. URL: http://dx.doi.org/10.1038/ejhg.2016.16, doi:10.1038/ejhg.2016.16. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2016.16)

[3. (Wu2019Screening) Qiqi Wu, Ruoyan Cao, Juan Chen, and Xiaoli Xie. Screening and identification of biomarkers associated with clinicopathological parameters and prognosis in oral squamous cell carcinoma. Experimental and Therapeutic Medicine, September 2019. URL: http://dx.doi.org/10.3892/etm.2019.7998, doi:10.3892/etm.2019.7998. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2019.7998)

[4. (Prasad2015Genetics) Rashmi Prasad and Leif Groop. Genetics of type 2 diabetes—pitfalls and possibilities. Genes, 6(1):87–123, March 2015. URL: http://dx.doi.org/10.3390/genes6010087, doi:10.3390/genes6010087. This article has 334 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes6010087)

[5. (Ishikawa2021A) Takahiro Ishikawa, Minoru Takemoto, Yoshihiro Akimoto, Aki Takada-Watanabe, Kunimasa Yan, Kenichi Sakamoto, Yoshiro Maezawa, Miyuki Suguro, Liqun He, Karl Tryggvason, Christer Betsholtz, and Koutaro Yokote. A novel podocyte protein, r3h domain containing-like, inhibits tgf-β-induced p38 mapk and regulates the structure of podocytes and glomerular basement membrane. Journal of Molecular Medicine, 99(6):859–876, February 2021. URL: http://dx.doi.org/10.1007/s00109-021-02050-w, doi:10.1007/s00109-021-02050-w. This article has 4 citations.](https://doi.org/10.1007/s00109-021-02050-w)